Arrowhead Pharmaceuticals, Inc. ARWR
Set alert
59.57 USD -0.33 -0.55%
At close · Nov 2
58.74 -0.83 -1.39%
After hours · Nov 2, 4:00 PM ET
59.41 Day range 61.17
37.06 52-week range 95.49
- YTD
- -10.27%
- 1 year
- +40.53%
- Open
- 60.55
- Prev close
- 59.90
- Mkt cap
- 8.39B
- Vol
- 1.31M
- Avg vol
- 1.72M
- EPS
- -2.28
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 59.41
- High
- 61.17
- Forward P/E
- -11.97
- Beta
- 1.37
- Short ratio
- 4.41
- Inst. own
- 85.26%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 24, 2026
- 50-d avg
- 69.79
- 200-d avg
- 71.73
- 1y target
- 107.71
MAX chart
Events in this range
- Aug 7, 2025Earnings: -1.26; estimate -0.94; surprise -34.04%
- Feb 5, 2026Earnings: 0.22; estimate 0.6; surprise -63.33%
- May 7, 2026Earnings: -0.93; estimate -1.09; surprise 14.68%
- Aug 4, 2026Earnings: -1.36; estimate -1.28; surprise -6.25%
- Sep 1, 2026Rating: HC Wainwright & Co. · Buy → Buy
Signals (125)
| Name | Date | Ago |
|---|---|---|
| MACD: Sell Signal | Nov 2, 2026 | 14 hours ago |
| SMA: Bearish | Sep 1, 2026 | 2 months ago |
| RSI: Overbought | Apr 1, 2026 | 7 months ago |
| RSI: Overbought | Nov 1, 2025 | 1 year ago |
| SMA: Bullish | Sep 1, 2025 | 1 year ago |
| SMA: Bullish | Aug 1, 2025 | 1 year ago |
| MACD: Buy Signal | Aug 1, 2025 | 1 year ago |
| MACD: Sell Signal | Feb 1, 2025 | 1 year ago |
| SMA: Bearish | Dec 1, 2024 | 1 year ago |
| SMA: Bullish | Nov 1, 2024 | 2 years ago |
| MACD: Buy Signal | Nov 1, 2024 | 2 years ago |
| MACD: Sell Signal | Oct 1, 2024 | 2 years ago |
| SMA: Bearish | Aug 1, 2024 | 2 years ago |
| SMA: Bullish | Jul 1, 2024 | 2 years ago |
| SMA: Bearish | Mar 1, 2024 | 2 years ago |
| MACD: Buy Signal | Jan 1, 2024 | 2 years ago |
| SMA: Bullish | Dec 1, 2023 | 2 years ago |
| SMA: Bearish | Aug 1, 2023 | 3 years ago |
| SMA: Bullish | Apr 1, 2023 | 3 years ago |
| SMA: Bearish | Jan 1, 2023 | 3 years ago |
Newest 20 of 125.
Financial health
Altman Z-Score
2.65 Grey zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
3 / 9 Weak
Nine pass/fail tests of profitability, leverage and efficiency.
FMP rating
D+1 / 5 overall
- DCF 1
- Return on Equity 1
- Return on Assets 1
- Debt / Equity 1
- P/E 1
- P/B 1
Valuation
P/E -2827×
FY 2016 5y median -19.8× FY 2025
P/S 5.6×
FY 2016 5y median 14.3× FY 2025
P/B 9.9×
FY 2016 5y median 10.6× FY 2025
P/FCF 29.4×
FY 2016 5y median -3.8× FY 2025
EV/EBITDA 28.8×
FY 2016 5y median -17.9× FY 2025
EV/Sales 5.7×
FY 2016 5y median 14.2× FY 2025
FCF Yield 3.4%
FY 2016 5y median -5.4% FY 2025
Profitability
Gross Margin 100.0%
FY 2016 5y median 95.7% FY 2025
Operating Margin 11.9%
FY 2016 5y median -85.2% FY 2025
Net Margin -0.2%
FY 2016 5y median -85.3% FY 2025
ROE -0.3%
FY 2016 5y median -44.2% FY 2025
ROIC 4.6%
FY 2016 5y median -30.6% FY 2025
ROA -0.1%
FY 2016 5y median -25.4% FY 2025
Growth (YoY)
Revenue 23258.2%
FY 2016 FY 2025
Operating Income 116.4%
FY 2016 FY 2025
EPS (diluted) 99.8%
FY 2016 FY 2025
Free Cash Flow 126.0%
FY 2016 FY 2025
Financial Health
Current Ratio 4.9×
FY 2016 5y median 4.0× FY 2025
Quick Ratio 4.9×
FY 2016 5y median 4.0× FY 2025
Debt / Equity 0.8×
FY 2016 5y median 0.8× FY 2025
Net Debt / EBITDA 0.8×
FY 2016 5y median 0.2× FY 2025
Interest Coverage 1.1×
FY 2016 5y median 0.0× FY 2025
Dividends
Dividend Yield 0.0%
FY 2016 5y median 0.0% FY 2025
Payout Ratio 0.0%
FY 2016 5y median 0.0% FY 2025
Annual · latest fiscal year ends 2025-09-30
